DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genentech

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

67 Comunicados de prensa

Ver todos los comunicados de prensa
20/01/2026
Biotecnología
Industria
Salud
Farmacéutica
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
Fuente
Genentech
Editor
Business Wire
1.00
0
22/12/2025
Industria
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
Fuente
Genentech
Editor
Business Wire
1.00
0
19/12/2025
Mercado laboral
Industria
Política Nacional
Salud
Farmacéutica
Biotecnología
Genentech Announces Agreement With U.S. Government
Fuente
Genentech
Editor
Business Wire
1.00
0
10/12/2025
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
Fuente
Genentech
Editor
Business Wire
1.00
0
18/11/2025
Industria
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
10/11/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Industria
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Fuente
Genentech
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Eventos
Ferias y Congresos
Industria
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
Fuente
Genentech
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Industria
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
Fuente
Genentech
Editor
Business Wire
1.00
0
28/10/2025
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
Fuente
Genentech
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0